Suppr超能文献

丙泊酚引起的心肌β-肾上腺素能受体结合及反应性改变。

Propofol-induced alterations in myocardial beta-adrenoceptor binding and responsiveness.

作者信息

Zhou W, Fontenot H J, Wang S N, Kennedy R H

机构信息

Department of Anesthesiology, University of Arkansas for Medical Sciences, Little Rock 72205, USA.

出版信息

Anesth Analg. 1999 Sep;89(3):604-8. doi: 10.1097/00000539-199909000-00011.

Abstract

UNLABELLED

Propofol (iv) depresses cardiovascular function in both humans and animals. However, the mechanism underlying this action has not been well described. The present study was designed to test the hypothesis that this effect of propofol results in part from an antagonism of adrenergic control of the heart. Experiments examined effects of propofol on: 1) [3H]CGP12177 (a beta-adrenoceptor antagonist) binding in rat myocardial membranes; and 2) the inotropic and chronotropic actions of isoproterenol in rat left atrial muscle and right atria, respectively. Propofol (25-200 microM) increased the apparent dissociation constant for [3H]CGP12177 without affecting binding site density. Similarly, 200 microM propofol increased the 50% effective concentration values for the dose-dependent positive chronotropic and inotropic actions of isoproterenol in right and left atria, and depressed the maximum increase in spontaneous rate elicited by this beta-adrenoceptor agonist. Other experiments demonstrated that propofol does not alter muscarinic receptor binding as monitored using [3H]quinuclidi-nylbenzilate. In conclusion, these results indicate that propofol can decrease cardiac beta-adrenoceptor responsiveness; however, the concentrations of propofol required suggest that this action contributes to the cardiovascular depression produced by this anesthetic only during large-dose bolus injection.

IMPLICATIONS

Experiments in membranes and cardiac preparations isolated from rat heart demonstrate that relatively high concentrations of propofol (25-200 microM) are required to antagonize beta-adrenoceptor binding and tissue responsiveness.

摘要

未标记

丙泊酚(静脉注射)会抑制人和动物的心血管功能。然而,这种作用的潜在机制尚未得到充分描述。本研究旨在验证丙泊酚的这种作用部分源于对心脏肾上腺素能控制的拮抗作用这一假设。实验研究了丙泊酚对以下方面的影响:1)大鼠心肌膜中[3H]CGP12177(一种β-肾上腺素能受体拮抗剂)的结合;2)异丙肾上腺素分别对大鼠左心房肌和右心房的变力性和变时性作用。丙泊酚(25 - 200微摩尔)增加了[3H]CGP12177的表观解离常数,而不影响结合位点密度。同样,200微摩尔丙泊酚增加了异丙肾上腺素在右心房和左心房剂量依赖性正性变时性和变力性作用的50%有效浓度值,并抑制了该β-肾上腺素能受体激动剂引起的自发频率最大增加。其他实验表明,丙泊酚不会改变用[3H]喹核酯监测的毒蕈碱受体结合。总之,这些结果表明丙泊酚可降低心脏β-肾上腺素能受体反应性;然而,所需的丙泊酚浓度表明,只有在大剂量推注期间,这种作用才会导致该麻醉剂产生的心血管抑制。

启示

从大鼠心脏分离的膜和心脏制剂实验表明,需要相对高浓度的丙泊酚(25 - 200微摩尔)来拮抗β-肾上腺素能受体结合和组织反应性。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验